SONUS ECHOGEN ULTRASOUND CONTRAST AGENT NDA FILING IN EARLY 1996
This article was originally published in The Gray Sheet
SONUS ECHOGEN ULTRASOUND CONTRAST AGENT NDA FILING IN EARLY 1996 is planned by the Bothell, Washington-based company, CEO Steven Quay, MD/PhD, told a Medical Investments Northwest conference in Seattle Sept. 12. A total of 45 patients of a planned 120 have completed Phase II trials, which began July 10. Initial indications will be diagnosis of cardiovascular disease, renal vascular disease/hypertension, and cancer, Quay said.
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.